U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809945) titled 'A Study of IBI3046 in Participants With Overweight or Obesity' on Sept. 03.
Brief Summary: This study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3046 in Chinese overweight or obese participants, comprising four phases: single ascending dose (SAD), multiple ascending dose (MAD), IBI3046 administration after mazdutide discontinuation, and IBI3046 in combination with mazdutide
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
Obesity and Overweight
Intervention:
DRUG: IBI3046
subcutaneous injection
DRUG: placebo
subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING...